A secondary analysis of a phase 3 trial suggests that patients with relapse within 3 months of treatment or persistent disease represent a distinct high-risk group.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/early-relapse-signals-high-risk-primary-refractory-lbcl-2026a1000as0?src=rss
Author :
Publish date : 2026-04-09 05:09:00
Copyright for syndicated content belongs to the linked Source.
